A Global Pregnancy Registry to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to YORVIPATH® (Palopegteriparatide) During Pregnancy and Breastfeeding

Recruiting now

Conditions studied: Hypoparathyroidism

In brief

The purpose of this registry study is to collect both prospective and retrospective data in women exposed to palopegteriparatide during pregnancy to assess risk of pregnancy and maternal complications, and adverse effects on the developing fetus, neonate, and infant and to assess infant outcomes through at least the first year of life.

Key facts

Study ID

NCT07345494

Run by

Ascendis Pharma A/S

People needed

50

Starts

2026-02-18

Expected to finish

2036-01-01

Last updated by the study team

2026-03-02

Who can join

Age: 15 and older, up to 50. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Participants aged 15 to 50 years
• Participants with exposure to at least one dose of YORVIPATH at any time within 15 days prior to conception and/or during pregnancy. The timeframe of 15 days prior to conception is calculated based on 5 times the YORVIPATH half life of \~ 60 hours
• Participants providing written informed consent, verbal consent, or eConsent (depending on country regulations) and a Medical Release of Information. For adolescents under the age of majority, verbal or written informed assent by the pregnant minor (where applicable) and verbal or written informed consent by the parent/legal guardian will be obtained.

You may not qualify if…

• Pregnancies in which only the male partner is exposed to at least one dose of YORVIPATH.

Where it is running

• Ascendis Investigational Site — Morgantown, West Virginia, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.